Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma

  • Tania S Bonny
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Eshan U Patel
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Xianming Zhu
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Evan M Bloch
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • M Kate Grabowski
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Alison G Abraham
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Kirsten Littlefield
    W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Ruchee Shrestha
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Sarah E Benner
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Oliver Laeyendecker
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Shmuel Shoham
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • David Sullivan
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Thomas C Quinn
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Arturo Casadevall
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Andrew Pekosz
    W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Andrew D Redd
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  • Aaron A R Tobian
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The efficacy of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is primarily ascribed as a source of neutralizing anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, the composition of other immune components in CCP and their potential roles remain largely unexplored. This study aimed to describe the composition and concentrations of plasma cytokines and chemokines in eligible CCP donors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A cross-sectional study was conducted among 20 prepandemic healthy blood donors without SARS-CoV-2 infection and 140 eligible CCP donors with confirmed SARS-CoV-2 infection. Electrochemiluminescence detection-based multiplexed sandwich immunoassays were used to quantify plasma cytokine and chemokine concentrations (n = 35 analytes). A SARS-CoV-2 microneutralization assay was also performed. Differences in the percentage of detection and distribution of cytokine and chemokine concentrations were examined by categorical groups using Fisher’s exact and Wilcoxon rank-sum tests, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among CCP donors (n = 140), the median time since molecular diagnosis of SARS-CoV-2 was 44 days (interquartile range = 38–50) and 9% (n = 12) were hospitalized due to COVID-19. Compared with healthy blood donor controls, CCP donors had significantly higher plasma levels of interferon (IFN)-γ, interleukin (IL)-10, IL-15, IL-21, and macrophage-inflammatory protein-1, but lower levels of IL-1RA, IL-8, IL-16, and vascular endothelial growth factor-A (P &lt; .0014). The distributions of plasma levels of IL-8, IL-15, and IFN-inducible protein-10 were significantly higher among CCP donors with high (≥160) versus low (&lt;40) anti-SARS-CoV-2 neutralizing antibody titers (P &lt; .0014). The median levels of IL-6 were significantly higher among CCP donors who were hospitalized versus nonhospitalized (P &lt; .0014).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Heterogeneity in cytokine and chemokine composition of CCP suggests there is a different inflammatory state among the CCP donors compared with SARS-CoV-2 naive, healthy blood donors.</jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ